JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel. Oppenheimer's 17th [...]
JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of [...]
JERUSALEM, May 2, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company is developing a new drug candidate, a weight loss treatment [...]
JERUSALEM, April 20, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the Company a patent titled, "Methods and Compositions for Treating Diabetes: [...]
JERUSALEM, April 4, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today a new paper co-authored by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, and Dr. Ehud Arbit. The paper, [...]
Presentation by Dr. Miriam Kidron, Chief Scientific Officer Date: Tuesday, March 28, 2017 Time: 10:45 a.m. EST Location: Royal Sonesta Boston, Cambridge, MA
JERUSALEM, March 22, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: [...]
JERUSALEM, March 21, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer. "We are very pleased to welcome Dr. Law to Oramed [...]
Oral insulin to be a game changer: Oramed CEO tells CNBC Squawk Box Asia Nadav Kidron, CEO of Oramed Pharmaceuticals, talks about the company's latest offering
Company Presentation by Josh Hexter, Chief Operating Officer Date: Wednesday, February 15, 2017 Time: 4:00 p.m. EST Location: Convene, NYC, Track 1 – Tribeca